Αναζήτηση αυτού του ιστολογίου

Δευτέρα 28 Ιουνίου 2021

Expression of LAT1 and 4F2hc in Gastroenteropancreatic Neuroendocrine Neoplasms

xlomafota13 shared this article with you from Inoreader

In Vivo. 2021 Jul-Aug;35(4):2425-2432. doi: 10.21873/invivo.12520.

ABSTRACT

BACKGROUND/AIM: Little is known about the expression of L-type amino acid transporter 1 (LAT1) and 4F2hc in gastroenteropancreatic-neuroendocrine neoplasms (GEP-NENs). Hence, we conducted a study to verify the clinicopathological significance of LAT1 and 4F2hc.

PATIENTS AND METHODS: Tissues from 126 patients with GEP-NENs were collected between August 2007 and September 2019 at our institution. We evaluated LAT1 and 4F2hc expression by immunohistochemistry, and examined their clinical significance.

RESULTS: No statistically significant associations were observed between LAT1 expression and the different NENs. Expression of 4F2hc was significantly different between neuroendocrine tumour (NET)-G1, NET-G2, and NET-G3 (p=0.029), and was significantly associated with vascular invasion (p=0.044) and the Ki-67 index (p=0.042).

CONCLUSION: No associat ion between LAT1 expression and malignant features in GEP-NENs was observed. However, an association between 4F2hc expression and the potential of malignancy in GEP-NENs was evident.

PMID:34182526 | DOI:10.21873/invivo.12520

View on the web

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.